Cheng Wei. Curriculum Vitate

●*Basic information*

Name: Cheng Wei
Nationality: China
Email: cheng.wei@ki.se
Phone: +46 734 892 400
Address: Fogdevreten 11, 17165 Solna, Stockholm, Sweden
H-index: 9

●*Education*

Karolinska Institutet (KI)	**– Postdoctor**		**2024/2026**
Tianjin Medical University (TMU)	**– Clinical medicine (Surgery, Neurosurgery)**	**PhD**	**2024/2021**
Tianjin Medical University (TMU)	**– Clinical medicine (Surgery, Neurosurgery)**	**Macademic master**	**2021/2018**
Southwest Medical University	**– Clinical medicine**	**Bachelor**	**2017/2012**

●*Research Background*

During my master's and PhD studies, my research focus was on the development and progression of glioblastoma and the mechanisms of chemotherapy resistance, where I gained some understanding of the pathological features and treatment challenges of glioblastoma. In my post-doctoral phase, I explored the mechanisms of tumor heterogeneity and plasticity in neuroblastoma at Karolinska Institute, Sweden. Neuroblastoma, as a highly heterogeneous pediatric tumor, poses unique challenges due to the dynamic interactions and plasticity between its different cell subtypes, significantly affecting disease progression and treatment resistance. I aim to systematically investigate the molecular mechanisms underlying the interswitching between the two major cell types in neuroblastoma and to identify potential therapeutic targets. Taking advantage of Karolinska Institute's advanced technology platforms and interdisciplinary collaboration opportunities, I am confident of translating these findings into clinical applications, thus contributing to the development of precision medicine strategies.

●*Publications*

➢***Wei C†***, Peng D†, Jing B†, Wang B, Li Z, Yu R, Zhang S, Cai J, Zhang Z, Zhang J, Han L. A novel protein SPECC1-415aa encoded by N6-methyladenosine modified circSPECC1 regulates the sensitivity of glioblastoma to TMZ. **Cell Mol Biol Lett.** 2024 Sep 27;29(1):127.

➢***Wei C†***, Zhang X†, Peng D†, Zhang X, Guo H, Lu Y, Luo L, Wang B, Li Z, He Y, Du X, Zhang S, Liang H, Li S, Wang S, Han L, Zhang J. LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway. **Cell Death Dis.** 2022 Nov 9;13(11):942.

➢***Wei C†***, Wang B†, Peng D†, Zhang X, Li Z, Luo L, He Y, Liang H, Du X, Li S, Zhang S, Zhang Z, Han L, Zhang J. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas. **Front Immunol.** 2022 Apr 4;13:849592.

➢***Wei C†***, Zhao L, Liang H, Zhen Y, Han L. Recent advances in unraveling the molecular mechanisms and functions of HOXA11-AS in human cancers and other diseases (Review). **Oncol Rep.** 2020 Jun;43(6):1737-1754.

➢Peng D†, ***Wei C†***, Jing B†, Yu R, Zhang Z, Han L. A novel protein encoded by circCOPA inhibits the malignant phenotype of glioblastoma cells and increases their sensitivity to temozolomide by disrupting the NONO-SFPQ complex. **Cell Death Dis.** 2024 Aug 25;15(8):616.

➢Zhang C†, ***Wei C†***, Huang X†, Hou C, Liu C, Zhang S, Zhao Z, Liu Y, Zhang R, Zhou L, Li Y, Yuan X, Zhang J. MPC-n (IgG) improves long-term cognitive impairment in the mouse model of repetitive mild traumatic brain injury. BMC Med. 2023 May 30;21(1):199.

➢Xu J†, ***Wei C†***, Wang C†, Li F, Wang Z, Xiong J, Zhou Y, Li S, Liu X, Yang G, Han L, Zhang J, Zhang S. TIMP1/CHI3L1 facilitates glioma progression and immunosuppression via NF-κB activation. Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167041.

➢Peng D†, ***Wei C†***, Zhang X†, Li S, Liang H, Zheng X, Jiang S, Han L. Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. Cancer Cell Int. 2021 Oct 26;21(1):566.

➢Zhang X†, ***Wei C†***, Liang H, Han L. Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. Front Oncol. 2021 Mar 12;11:587554.

➢Zhang X†, Li Z†, ***Wei C†***, Luo L, Li S, Zhou J, Liang H, Li Y, Han L. PLK4 initiates crosstalk between cell cycle, cell proliferation and macrophages infiltration in gliomas. Front Oncol. 2022 Dec 22;12:1055371.

➢Li Z†, ***Wei C†***, Zhang Z, Han L. ecGBMsub: an integrative stacking ensemble model framework based on eccDNA molecular profiling for improving IDH wild-type glioblastoma molecular subtype classification. Front Pharmacol. 2024 Apr 11;15:1375112.